The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISH 2022 | The future of daratumumab in multiple myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares her perspectives on the future use of daratumumab in multiple myeloma. Potential uses include combination with bispecific monoclonal antibodies, maintenance therapy or complement to CAR-Ts. Dr Mateos highlights the versatility of daratumumab in all stages of multiple myeloma. This interview took place at the 38th World Congress of the International Society of Hematology 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
